Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals' thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals thiomersal-reduced adjuvanted influenza vaccine in adults aged 65 years and above.

Trial Profile

A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals' thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals thiomersal-reduced adjuvanted influenza vaccine in adults aged 65 years and above.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 576389A (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 25 May 2012 Actual patient number changed from 834 to 720 added as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual patient number (834) added as reported by ClinicalTrials.gov.
    • 30 Apr 2008 Status change from in progress to completed, according to clinicaltrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top